16 hours ago · Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide later this year, which is a few months earlier than expected.

16 hours ago · Eli Lilly and Company (NYSE: LLY) has announced that it will release late-stage data on its next-generation weight loss drug, retatrutide, in 2025, earlier than initially expected.

11 hours ago · The word out of Eli Lilly said that it would be bringing out data from a “late-stage trial” on retatrutide, its latest weight loss drug candidate, ahead of schedule.

Aug 27, 2024 · Eli Lilly is making tirzepatide, branded as Zepbound for weight loss, available in vials for patients who pay out-of-pocket.

Jun 26, 2023 · An experimental drug from Eli Lilly helped patients with obesity lose an average of 24% of their body weight over 48 weeks on the highest dose in a mid-stage study, the most weight loss seen yet...

Nov 8, 2023 · Adults taking Zepbound in a clinical trial lost on average 48 lb. at the highest dose. Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP and GLP-1, to tackle an underlying cause of excess weight.

The Food and Drug Administration on Wednesday approved Zepbound, a new weight loss drug from drugmaker Eli Lilly that was shown in clinical trials to help people lose up to 52 pounds in 16...

Oct 15, 2023 · In a co-primary endpoint, following the lead-in period, participants taking tirzepatide achieved an additional 21.1% mean weight loss. In a secondary endpoint, participants achieved a total mean weight loss of 26.6% (29.2 kg or 64.4 lb.) from study entry over 84 weeks.

Nov 9, 2023 · Here’s what you need to know about Lilly’s new drug. How well does Zepbound work? The active ingredient in Zepbound is tirzepatide, which mimics a hormone that helps reduce food cravings.

INDIANAPOLIS, April 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in results from SURMOUNT-2.